CCL2 and atherosclerosis: The fact that chronic treatment with T0901317 increased liver triglyceride levels and macrophage content may, thus, explain the observed increase in plasma MCP-1 levels and the associated rise in blood monocyte levels and atherosclerosis susceptibility.